-Zaneta Nikolovska-Coleska Researcher Activity Profile

Research Author Detailed Information 

Zaneta Nikolovska-Coleska Publication Rate By Year

Zaneta Nikolovska-Coleska has published 1 paper(s) in 2004, 1 paper(s) in 2005, 5 paper(s) in 2006, 8 paper(s) in 2007, 4 paper(s) in 2008, for a total of 19 research publications in total.

Zaneta Z Nikolovska-Coleska Author Information

LAST NAME: nikolovska-coleska

FIRST NAME: zaneta

INITIALS: Z

AFFILIATION:

Papers

Zaneta Nikolovska-Coleska's Publication Record

1. Pyrogallol-based molecules as potent inhibitors of the antiapoptotic Bcl-2 proteins. Year Published: 2007
Department of Internal Medicine, Comprehensive Cancer Center, and Life Sciences Institute, University of Michigan, 1500 East Medical Center Drive, Ann Arbor, Michigan 48109, USA.
2. Antiangiogenic effect of TW37, a small-molecule inhibitor of Bcl-2. Year Published: 2006
Angiogenesis Research Laboratory, Department of Restorative Sciences, School of Dentistry, University of Michigan, Ann Arbor, MI 48109-1078, USA.
3. Design, synthesis, and characterization of new embelin derivatives as potent inhibitors of X-linked inhibitor of apoptosis protein. Year Published: 2006
Comprehensive Cancer Center and Departments of Internal Medicine, Pharmacology and Medicinal Chemistry, University of Michigan, 1500 E. Medical Center Drive, Ann Arbor, MI 48109, USA.
4. Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins. Year Published: 2006
Comprehensive Cancer Center and Department of Internal Medicine, University of Michigan, 1500 E. Medical Center Drive, Ann Arbor, Michigan 48109, USA.
5. A novel BH3 mimetic reveals a mitogen-activated protein kinase-dependent mechanism of melanoma cell death controlled by p53 and reactive oxygen species. Year Published: 2006
Department of Dermatology, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI 48109, USA.
6. Design, synthesis, and evaluation of a potent, cell-permeable, conformationally constrained second mitochondria derived activator of caspase (Smac) mimetic. Year Published: 2006
Comprehensive Cancer Center, Department of Internal Medicine, University of Michigan, 1500 E. Medical Center Drive, Ann Arbor, MI 48109, USA.
7. (alpha/beta+alpha)-peptide antagonists of BH3 domain/Bcl-x(L) recognition: toward general strategies for foldamer-based inhibition of protein-protein interactions. Year Published: 2007
Department of Chemistry, University of Wisconsin, Madison, Wisconsin 53706, USA.
8. Structure-based design of flavonoid compounds as a new class of small-molecule inhibitors of the anti-apoptotic Bcl-2 proteins. Year Published: 2007
Comprehensive Cancer Center and Department of Internal Medicine, University of Michigan, 1500 East Medical Center Drive, Ann Arbor, Michigan 48109, USA.
9. Small molecule inhibitors of the MDM2-p53 interaction discovered by ensemble-based receptor models. Year Published: 2007
Department of Medicinal Chemistry and the Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI 48109, USA.
10. Design, synthesis, and characterization of a potent, nonpeptide, cell-permeable, bivalent Smac mimetic that concurrently targets both the BIR2 and BIR3 domains in XIAP. Year Published: 2007
Department of Internal Medicine and Comprehensive Cancer Center, University of Michigan, 1500 E. Medical Center Drive, Ann Arbor, Michigan 48109, USA.
11. Small molecule inhibitors of the MDM2-p53 interaction discovered by ensemble-based receptor models. Year Published: 2007
Department of Medicinal Chemistry and the Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI 48109, USA.
12. Small molecule inhibitors of the MDM2-p53 interaction discovered by ensemble-based receptor models. Year Published: 2007
Department of Medicinal Chemistry and the Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI 48109, USA.
13. Structure-based design of potent, conformationally constrained Smac mimetics. Year Published: 2004
Departments of Internal Medicine and Medicinal Chemistry and Comprehensive Cancer Center, University of Michigan, 1500 East Medical Center Drive, Ann Arbor, MI 48109, USA.
14. Structure-based design of potent non-peptide MDM2 inhibitors. Year Published: 2005
Departments of Internal Medicine and Medicinal Chemistry and Comprehensive Cancer Center, and Life Sciences Institute, University of Michigan, 1500 East Medical Center Drive, Ann Arbor, Michigan 48109, USA.
15. Design and characterization of bivalent Smac-based peptides as antagonists of XIAP and development and validation of a fluorescence polarization assay for XIAP containing both BIR2 and BIR3 domains. Year Published: 2008
Departments of Internal Medicine, Pharmacology, and Medicinal Chemistry and Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI 48109, USA.
16. Design, synthesis, and characterization of a potent, nonpeptide, cell-permeable, bivalent Smac mimetic that concurrently targets both the BIR2 and BIR3 domains in XIAP. Year Published: 2007
Department of Internal Medicine and Comprehensive Cancer Center, University of Michigan, 1500 E. Medical Center Drive, Ann Arbor, Michigan 48109, USA.
17. Acylpyrogallols as inhibitors of antiapoptotic bcl-2 proteins. Year Published: 2008
shaomeng@umich.edu.
18. Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. Year Published: 2008
Comprehensive Cancer Center and Department of Internal Medicine, University of Michigan, 1500 East Medical Center Drive, Ann Arbor, MI 48109, USA.
19. Acylpyrogallols as inhibitors of antiapoptotic Bcl-2 proteins. Year Published: 2008